Healthcare Triangle, Inc. Form 8-K Summary
Business Context and Reporting Period
Healthcare Triangle, Inc. filed a Form 8-K dated April 1, 2022, reporting events occurring March 30–31, 2022. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol HCTI. The filing concerns changes to the board of directors and board committees; it does not report operating or financial results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- Vivek Prakash resigned from the board effective March 30, 2022. He had served as Audit Committee chair and financial expert, Compensation Committee chair, and Nominating and Corporate Governance Committee chair.
- Brendan Gallagher resigned from the board effective March 30, 2022. His resignation affected his membership on the Compensation and Nominating and Corporate Governance Committees.
- The board reduced its size from eight members to seven.
- On March 31, 2022, the board appointed Jeffrey S. Mathiesen as a director and Audit Committee chair and financial expert. He also joined the Compensation Committee.
- The Audit Committee now consists of April Bjornstad, John Leo, and Mr. Mathiesen; the Compensation Committee consists of Mr. Mathiesen, Mr. Leo, and Dave Rosa; and the Nominating and Corporate Governance Committee consists of Ms. Bjornstad, Mr. Rosa, and Mr. Leo.
Compensation, Outlook, and Risks
- Under the Appointment Letter Agreement, Mr. Mathiesen will receive an annual grant of options to purchase 20,000 shares, with an exercise price equal to the closing sale price on the grant date. The options vest after one year and generally remain exercisable until the earlier of five years after grant or 18 months after service ends.
- Mr. Mathiesen will receive a quarterly cash stipend of $5,000, plus $2,500 per quarter for each committee chairmanship or service as Board chairman, and reimbursement of qualifying travel and related expenses.
- The resignations were stated not to result from disagreements with the company regarding its operations, policies, or practices.
- The filing provides no financial guidance, operating outlook, contingencies, or material risk updates.
Investor Verification Items
- Review Exhibit 10.1 for the complete terms of Mr. Mathiesen’s appointment and equity compensation.
- Confirm the post-appointment board and committee composition in subsequent filings and proxy materials.
- Assess the effect of the board turnover and new Audit Committee financial expert on governance and reporting oversight.
- Obtain the company’s periodic financial filings for revenue, profitability, cash flow, debt, liquidity, and forward guidance, which are not included in this 8-K.